1
|
Kolyadina IV, Bolotina L, Zhukova L, Vladimirova LY, Sultanbaev A, Karabina E, Ganshina I, Ovchinnikova E, Kolyadina IV, Antonova G, Volkonsky M, Kolokolov J, Zueva E, Akopyan I, Fadeeva N, Evstigneeva I, Orlova S, Vasilevskaya A, Shalaeva O, Shirokova O. The effectiveness and safety of eribulin therapy in HR-positive HER2-negative metastatic breast cancer post-CDK4/6 inhibitor therapy in Russian clinical practice. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13035 Background: EMPOWER trial demonstrated the benefit of eribulin administrated post CD4/6i in patients (pts) with HR+ HER2-negative (HR+HER2-) metastatic breast cancer (MBC). There are several important limitations to this trial: > 60% of pts were stage IV at the time of treatment initiation, eribulin used in late lines (2L only in 30% pts) and follow-up data were immature. Current study aimed to provide additional data on the real-world effectiveness and safety of eribulin monotherapy in this setting. Methods: Observation study of eribulin monotherapy in standard regimen enrolled 54 pts (median age 56; range 29-79 years) with HR+ HER2- MBC received at least one dose of eribulin post CDK 4/6i in metastatic settings; 24% pts had de novo metastatic BC, 76% - recurrent BC; 77% received palbociclib, 21% ribociclib, 2% both drugs; 49% pts received CDK4/6i with fulvestrant and 51% with AI. CDK4/6i was used: 49% pts in 1L, 36% in 2L, 16% in 3L. Median DOR of CDK4/6i treatment was 9.07 months (range 2-38). 94% pts received anthracyclines and taxanes, eribulin was used in 2L in 60%, 30% in 3L, 8% in 4L, 2% in 5L. The most common sites of metastases (Mts) were bones (78%), liver (73%), lung (56%) and brain (8%); visceral Mts were seen in 90% pts. Median follow-up – 11,5 months (range 3-36). Results: Median cycles of eribulin therapy was 10,5 (range 1-44); objective response rate was seen in 24%, stabilization - 67%, progression - in 9%. Median PFS was 10.0 months, there were no significant differences in the different subgroups (visceral/no visceral; recurrent/de novo BC; age; CDK4/6i as 1L vs 2L, fulvestrant vs AI), p > 0,05. Median PFS was higher in pts with lung Mts vs non-lung (24 vs 9,1 months, p = 0.056). Most common AEs all grades were neutropenia (26%), anemia (9%), asthenia (9%), polyneuropathy (11.1%). AE did not affect the effectiveness of eribulin (p = 0.648). Dose reduction was in 19% pts and did not affect the effectiveness of eribulin (p = 0.612). At median follow-up of 11.5 months, 92.5% of patients still alive. Conclusions: As post-CDK4/6i therapy, eribulin in HR+HER2- MBC pts was effective and well tolerated, regardless of age, line of CDK4/6, CDK 4/6i combination partner. Patients with metastasis to the lung have better mPFS. Results in this real-world population of pts with HR+HER2- MBC were consistent with the EMPOWER study, and support administration of eribulin in 2-3 lines as an effective option for post-CD4/6i pts.
Collapse
Affiliation(s)
- Irina Vladimirovna Kolyadina
- Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation, Moscow, Russian Federation
| | - Larisa Bolotina
- National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
| | - Lyudmila Zhukova
- N. N. Blokhin Cancer Research Center, Moscow, Russian Federation
| | | | - Alexander Sultanbaev
- Republic Clinical Oncology Dispensary of Bashkortostan Republic, Ufa, Russian Federation
| | - Elena Karabina
- Tula Regional Oncology Dispensary, Tula, Russian Federation
| | - Inna Ganshina
- Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation, Moscow, Russian Federation
| | - Elena Ovchinnikova
- Nizhegorodskiy Regional Clinical Oncology Dispensary, Nizhniy Novgorod, Russian Federation
| | | | - Galina Antonova
- Moscow City Clinical Hospital #40, Moscow, Russian Federation
| | | | | | - Elena Zueva
- Moscow City Clinical Oncology Hospital #1, Moscow, Russian Federation
| | - I Akopyan
- Moscow City Clinical Hospital named after Bakrusheny, Moscow, Russian Federation
| | - Natalia Fadeeva
- Chelyabinsk Regional Center of Oncology and Nuclear Medicine, Chelyabinsk, Russian Federation
| | | | - Svetlana Orlova
- Republic Clinical Oncology Dispensary of Chuvash Republic, Cheboksary, Russian Federation
| | | | - Oxana Shalaeva
- Perm Regional Oncology Dispensary, Perm, Russian Federation
| | - Oxana Shirokova
- Ekaterinburg Regional Oncology Dispensary, Ekaterinburg, Russian Federation
| |
Collapse
|
2
|
Kovalenko E, Manzyuk L, Gorbunova V, Kolyadina I, Bolotina L, Zhilyaeva L, Ponomarenko D, Karabina E, Mukhametshina G, Khasanova A, Ekaterina R, Safarova A, Manikhas A, Volkonsky M, Kramskaya L, Karandeeva T, Suslova I, Popova N, Evstigneeva I, Shumskaya I. Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30684-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
3
|
Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A, Khalimov A, Karabina E, Shikina V, Abdelgafur A, Statsenko G, Titova I, Isaichikov D, Makarnyaeva G, Mordovskiy A, Barkovskaya O, Smirnov A, Gikalo M, Savelov N, Kosov D, Imyanitov E, Demidova I, Tjulandin S. Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study. J Glob Oncol 2020; 5:1-7. [PMID: 31095455 PMCID: PMC6550093 DOI: 10.1200/jgo.19.00024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The overall survival (OS) results in patients with ALK-positive metastatic non–small-cell lung cancer (NSCLC) have rarely been reported. The aim of this prospective-retrospective cohort study was to obtain real-world data on the use of crizotinib or chemotherapy in patients with ALK-positive metastatic NSCLC in Russia. PATIENTS AND METHODS Patients with epidermal growth factor receptor–negative metastatic NSCLC were screened in 23 cancer centers. To be eligible, patients were required to have confirmation of ALK rearrangement. Patients were treated with crizotinib (250 mg twice daily; n = 96) or the investigator’s choice of platinum-based chemotherapy (n = 53). The primary end point was OS. RESULTS A total of 149 ALK-positive patients were included. Mean age was 53 years in both groups. Patients were predominately women (59%) and never-smokers (74%), and most patients had adenocarcinoma histology (95%). At a median follow-up time of 15 months, 79 of the 149 patients included in the analysis had died. Median OS from the start of treatment was 31 months (95% CI, 28.5 to 33.5 months) in the crizotinib group and 15.0 months (95% CI, 9.0 to 21.0 months) in the chemotherapy group (P < .001). The objective response rate was 34% in the crizotinib group. Among patients with brain metastasis, one complete response (6%) and five partial responses (31%) were achieved. Grade 3 adverse events were observed in three patients (3%) in the crizotinib group. CONCLUSION The improved OS observed in crizotinib clinical trials in ALK-positive NSCLC was also observed in the less selective patient populations treated in daily practice in Russia. The use of standard chemotherapy in these patients remains common but seems inappropriate as a result of the effectiveness of newer treatments, such as crizotinib.
Collapse
Affiliation(s)
| | | | - Sergei Orlov
- Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia
| | - Elena Filippova
- Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia
| | | | | | | | | | | | | | | | - Irina Titova
- A.I. Kryzhanovsky Krasnoyarsk Cancer Center, Krasnoyarsk, Russia
| | | | | | | | | | | | | | | | - Dmitry Kosov
- Aston Health Contract Research Organization, Moscow, Russia
| | | | | | - Sergei Tjulandin
- Russian Society of Clinical Oncology, Moscow, Russia.,N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
| |
Collapse
|
4
|
Volkova M, Abdelgafur A, Amoev Z, Aivazov M, Babina KG, Borisov PS, Evstigneeva I, Samuseva OI, Kalpynsky A, Karabina E, Kirdakova N, Kuzmina E, Latipova DH, Ovchinnikova EG, Olshanskaya AS, Protsenko S, Semiglazova T, Smirnov R, Usynin E, Chernyakova I. Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.644] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
644 Background: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy. Methods: Russian multicenter observational study included 73 consecutive patients with morphologically verified mRCC progressed during or following ≥1 line of antiangiogenic targeted therapy, treated with lenvatinib (18 mg/d) and everolimus (5 mg/d) in 20 Russian centers. Median age of the patients was 59 (23-73) years, a male-to-female ratio - 3:1. Most common histological type of kidney cancer was clear-cell RCC (71 (95.8%)). More than 2 lines of previous treatment were administered in 45 (61.6%) cases. Most patients were diagnosed with multiple metastases (71 (97.3%)) in >1 site (61 (83.6%)). Nephrectomy was performed in 87.7% (64/73) of cases. At the combined therapy start ECOG PS 2-4 was registered in 16 (20.5%), poor prognosis according to IMDC score – in 33 (45.2%) patients. Median follow-up was 9.7 (1-26) months. Results: objective response rate was 11% (8/73); tumor control was reached in 93.2% (68/73) of cases. Median objective response duration was 10.5 (4.3-16.8) months, tumor control duration – 10.0 (2.5-17.5) months. Median progression-free survival (PFS) achieved 16.9 (95% confidence intervals (CI): 12.1-20.6), overall survival (OS) – 20.8 (95% CI: 15.7-25.9) months. Any adverse events (AE) developed in 83.6% (61/73), AE grade 3-5 - in 23.3% (17/73) of cases. Most frequent AE grade 3-4 were diarrhea (10 (13.6%)) and arterial hypertension (6 (8.2%)). Unacceptable toxicity demanded treatment cancellation in 4.2% (3/73), therapy interruption – in 30.1% (22/73) and dose reduction – in 32.9% (24/73) of patients. Conclusions: unselected mRCC patients administered with combined targeted therapy in the real world practice were registered with lower objective response rate, similar survival and better tolerability comparing with population assigned for lenvatinib plus everolimus in the randomized phase II trial.
Collapse
Affiliation(s)
- Maria Volkova
- N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | - Ahmed Abdelgafur
- Republican Clinical Oncological Center, Cheboksary, Russian Federation
| | - Zurab Amoev
- Federal State Budgetary Institution “Volga Regional Medical Center”, Nizny Novgorod, Russian Federation
| | - Magomed Aivazov
- State Healthcare Institution OD №4 DZM, Moscow, Russian Federation
| | | | - Pavel S. Borisov
- City Clinical Oncology Center, St. Petersburg, Russian Federation
| | | | - Olga Igorevna Samuseva
- FSBI "National Medical Research Oncology Center named after N.N. Blokhin " Ministry of Health of Russian Federation, Moscow, Russian Federation
| | | | | | - Natalia Kirdakova
- State Healthcare Institution State Clinical Hospital No. 1 DZM, Moscow, Russian Federation
| | - Evgeniya Kuzmina
- Salekhard Clinical Hospital, Yanao, Salekhard, Russian Federation
| | - Dilorom H. Latipova
- National Medical Research Center of Oncology na N.N. Petrov Ministry of Healthcare of Russian Federation, St. Petersburg, Russian Federation
| | | | - Anna Sergeevna Olshanskaya
- FSBI "National Medical Research Oncology Center named after N.N. Blokhin "of the Ministry of Health of Russia, Moscow, Russian Federation
| | - Svetlana Protsenko
- N.N.Petrov Research Institute of Oncology, St. Petersburg, Russian Federation
| | - Tatiana Semiglazova
- National Medical Research Center of Oncology na N.N. Petrov Ministry of Healthcare of Russian Federation, St. Petersburg, Russian Federation
| | - Roman Smirnov
- Vologda Oblast Clinical Hospital 1, Vologda, Russian Federation
| | - Evgeny Usynin
- FBGU Tomsk Scientific Research Center, Tomsk, Russian Federation
| | - Irina Chernyakova
- State Healthcare Institution of the Republic of Karelia “Republican Oncology Dispensary", Petrozavodsk, Russian Federation
| | | |
Collapse
|
5
|
Zhukova L, Gorbunova V, Manzyuk L, Kovalenko E, Kalyadina I, Bolotina L, Popova N, Golberg V, Karandeeva T, Alexey M, Marfutov V, Filonenko D, Vladimirova L, Tarasova A, Shaidorov M, Zhilyaeva L, Ponomarenko D, Karabina E, Mukhametshina G, Khasanova A, Evstigneeva I, Chernyakova E. LONG-TERM RESPONDERS WITH METASTATIC BREAST CANCER (MBC) RECEIVING ERIBULIN: REAL LIFE EXPERIENCE. Breast 2019. [DOI: 10.1016/s0960-9776(19)30678-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Vladimirova LY, Fedyanin M, Chubenko V, Fakhrudinova O, Bolotina L, Moiseenko FV, Khasanova A, Belonogov A, Musaeva H, Novikova O, Stradaeva I, Mukhametshina G, Orlova R, Feoktistova P, Kuzmina E, Karabina E, Nekrasova O, Sherstnev V, Micshenko A, Tjulandin S. Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e15007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15007 Background: Afl is one of the antiagiogenic agents used for the treatment for mCRC. Cardiovascular toxicity of Afl is shown to be a main reason of the drug discontinuation but there are no studies on factors associated with nonhem adverse events(AEs). The aim of the study was to define clinical factors associated with the development of Gd.3-4 nonhem AEs. Methods: Pts with mCRC treated with FOLFIRI+Afl were included in a multicenter prospective base from 2016-18. Multivariative regression analysis was performed with Chicago, IL v.22.0. Factors studied included demographic, disease characteristics, data about concomitant diseases(CD) and concomitant medications. Results: 278 pts with mCRC from 18 centers were included. Mean age – 58.7, 48.6% were male, mean number of metastases– 2. ECOG 0-1–97.5%pts. RASm had 133 (47.8%) pts. Afl+FOLFIRI was used as the 2nd line therapy–in 67.6%. CD were in 194 (69.8%), cardiovascular–in 175 (62.9%). ORR(CR+PR)17.3%, SD-43.9%. MedPFS was 6.0 mos. Afl discontinuation due to AEs 11.9%. AE were reported in 201 (72.3%), Gd3-4 – in 69 (24.8%); nonhem AEs – in 178 (64%), Gd3-4–52 (18.8%)pts. Among Gd3-4 nonhem AEs were arterial hypertension Gd1-2–77 (27.7%), Gd3-4-in 36 (12.9%), vomiting Gd1-2–45 (16.2%), diarrhea Gd1-2–in 32 (11.5%), asthenia Gd1-2 –in 29 (10.4%), hepatotoxicity Gd1-2–in 2(5%), thrombosis–in 2 (5%) pts. Multivariate regression analysis showed that among the factors studied number of lines of treatment (OR1.4,95%CI1.1-2.1,p=0.03) and CD requiring medical support (OR 2.0,95%CI1.1-3.7,p=0.03) were found as independent factors of nonhem AE Gd3-4 development. ACE-inhibitors (OR2.2,95%CI1.2-4.3,p=0.02), calcium-channel blockers (CCB)(OR4.1,95%CI1.6-10.4,p=0.003 ) were the medical drugs considered to be significant. Conclusions: Number of lines and CD requiring medical support, especially with ACE-inhibitors or CCB, identifies a significant risk of developing cardiovascular non-hem AEs Gd3-4 with FOLFIRI + Afl.
Collapse
Affiliation(s)
| | - Mikhail Fedyanin
- Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation
| | - Viacheslav Chubenko
- Clinical and Research Center of Specialized Types of Medical Care (Oncological), St. Petersburg, Russia
| | - Olga Fakhrudinova
- Clinical and Research Center of Specialized Types of Medical Care (Oncological), St. Petersburg, Russian Federation
| | - Larisa Bolotina
- Р.A. Hertsen Moscow Oncology Research Institute – branch of National Medical Research Radiological Centre of Ministry of Health of the Russian Federation (RF), Moscow, Russian Federation
| | - Fedor Vladimirovich Moiseenko
- Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncological), Saint-Petersburg, Russian Federation
| | | | | | - Hedi Musaeva
- Oncological Dispensary, Grozny, Russian Federation
| | - Olga Novikova
- Khabarovsk Regional Cancer Center, Khabarovsk, Russian Federation
| | | | | | - Rashida Orlova
- Saint-Petersburg State University, Saint-Petersburg, Russian Federation
| | | | - Evgeniya Kuzmina
- Salekhard Clinical Hospital, Yanao, Salekhard, Russian Federation
| | | | | | | | | | - Sergei Tjulandin
- Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation
| |
Collapse
|
7
|
Filonenko D, Gorbunova V, Manzyuk L, Kovalenko E, Zhukova L, Bolotina L, Kolyadina I, Manikhas A, Zhilyaeva L, Karabina E. Efficacy and safety of eribulin in patients with metastatic breast cancer in early and late application: real life experience. Breast 2019. [DOI: 10.1016/s0960-9776(19)30243-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Gorbunova V, Manzyuk L, Kovalenko E, Bolotina L, Semiglazova T, Zhilyaeva L, Karabina E, Ponomarenko D, Khasanova A, Evstigneeva I, Mukhametshina G. Long-term responders with metastatic breast cancer (MBC) receiving eribulin: Real life experience. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e13065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Vera Gorbunova
- N. N. Blokhin Cancer Research Center, Moscow, Russian Federation
| | - Ludmila Manzyuk
- Russian Cancer Scientific Centre, Moscow, Russian Federation
| | | | - Larisa Bolotina
- Р. Hertsen Moscow Oncology Research Institute – branch of National Medical Research Radiological Centre of Ministry of health of the Russian Federation, Moscow, Russia
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Manikhas A, Kovalenko E, Manzyuk V, Bolotina LV, Zhilyaeva L, Karabina E, Ponomarenko D. Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: Real life experience. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e12580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12580 Background: Eribulin demonstrates improved overall survival compared to standard treatments, Her2-negative and TNBC patients have the most survival benefit. We sought to describe treatment patterns of eribulin and clinical outcomes among TNBC patients with advanced breast cancer treated in community oncology practices across the Russian Federation. Methods: Patients treated with eribulin anytime between January 1, 2014 and January 1, 2017 with a diagnosis of MBC were identified by providers within the Russia Oncology Research Center. Providers reviewed the health records (electronic or paper-based) and abstracted selected data points into an electronic case report form for each eligible patient. Results: A total 52 TNBC patients were considered by 10 providers. A median of age at start of eribulin was 47,5 (39-55) yrs and ECOG status 0-1 were assessed. Most of the pts (92,3%) had visceral mts, a median number metastatic disease regions was 2 (1-3). Eribulin was administered as the 1st and 2nd line of BC treatment to 14 (26,9%) pts, 3rd line – to 9 (17,3%), the 4thand later lines – to 29 (55,8%) pts. Objective response occurred in 5 (9,6%) pts. Stable disease registered in 24 (46,1%) pts. Median PFS was 3,0 months (95% CI 1,9-8,55). Overall the drug was well tolerated. The most common type of toxicity was hematologic. Neutropenia gr II was observed in 8 (15,4) pts and III-IV gr in 6 (11,5%), two cases of febrile neutropenia were registered. 4 (7,7%) pts experienced fatigue gr II. Peripheral neuropathy gr II was observed in 4 (7,7%) pts. Dose reduction due to toxicity was performed in 8 (15,4%) pts. Treatment was never withdrawn due to toxicity. Conclusions: This is the first real-life study of clinical outcomes, for patients initiating eribulin therapy for TNBC in community oncology practices throughout the Russian Federation. . Our experience with Eribulin in TNBC patients confirms it efficacy and safety in all lines of treatment, including intensively pretreated patients in this hard-to-treat population.
Collapse
Affiliation(s)
- Alexey Manikhas
- City Clinical Oncology Dispensary, St. Petersburg, Russian Federation
| | - Elena Kovalenko
- Russian Cancer Scientific Centre, Moscow, Russian Federation
| | - Valentina Manzyuk
- N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
| | | | | | - Elena Karabina
- Tula Regional Oncology Dispensary, Tula, Russian Federation
| | | |
Collapse
|
10
|
Manzyuk V, Gorbunova V, Kovalenko E, Bolotina LV, Semiglazova T, Ponomarenko D, Zhilyaeva L, Mukhametshina V, Karabina E. Efficacy and safety of eribulin in patients with metastatic breast cancer at early and late application: Real-life experience. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e12579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12579 Background: We sought to describe treatment patterns of eribulin and clinical outcomes associated with early and late use among anthracycline and taxane-pretreated patients with advanced breast cancer treated in community oncology practices across the Russian Federation. Methods: Patients treated with eribulin anytime between Jan1, 2014 and Jan 1, 2017 with a diagnosis of MBC were identified by providers within the Russia Oncology Research Center. Providers reviewed the health records and abstracted selected data points into an electronic case report form for each eligible patient. Results: A total 113 MBC patients were considered by 16 providers. A median age was 53 (44-58) yrs and ECOG status 0-1 were assessed. 57 (50,5%) pts were ER/PR-positive, 37 (32,7%) – triple-negative, 19 (16,8%) – HER2-positive (in combination with trastuzumab). Most of the pts (96,5%) had visceral mts, a median number metastatic disease regions was 2 (1-3). Eribulin was administered as the 1st and 2nd line of MBC treatment to 36 (32%) pts (early application), the 3rd and later lines (late application) – to 77 (68%) pts. Clinical response rate (ORR and SD ≥ 6 months) was 44% among early line treated patients (first and second-line combined) and 38% among late line eribulin treated patients. Median PFS was 4,89 months (95% CI 2,84-8,00) among early users and 3,96 months (95% CI 2,04-7,99) among later users. The effectiveness in early eribulin application group was higher, but difference was not statistically significant. Tolerability of the drug was good: withdrawn due to toxicity had 3,5%, dose reduction – 13, 3% of pts. The most common type of toxicity was hematological with neutropenia Gr II in 12 (10,6%) of pts and Gr III – in 8 (7,1%) of pts and 2 pts had febrile neutropenia. 6 (5,3%) pts experienced fatigue Gr II. Peripheral neuropathy Gr II was observed in 8 (7,1%) of pts. Conclusions: This is the first real-life description of clinical outcomes, for patients initiating eribulin therapy for MBC throughout the Russian Federation. Our experience with Eribulin in MBC patients confirms it efficacy and safety in early lines of treatment and intensively pretreated patients.
Collapse
Affiliation(s)
- Valentina Manzyuk
- N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
| | - Vera Gorbunova
- N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
| | - Elena Kovalenko
- Russian Cancer Scientific Centre, Moscow, Russian Federation
| | | | | | | | | | | | - Elena Karabina
- Tula Regional Oncology Dispensary, Tula, Russian Federation
| |
Collapse
|
11
|
Korkontzelos I, Tsimoyiannis E, Zagaliki A, Demou A, Karabina E, Antoniou N. Pelvic retroperitoneal schwannoma presenting as a gynecologic mass: case report. EUR J GYNAECOL ONCOL 2005; 26:117-9. [PMID: 15755018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Schwannomas of the sacral plexus are retroperitoneal tumors, usually benign, that result from proliferation of perineural cells. They are rare, pelvic, well defined tumors that present infrequently as gynecologic masses. Misdiagnosis is not uncommon in these cases, since these masses are not often encountered in clinical practice and preoperative imaging methods can be only suggestive of the diagnosis. Furthermore, these masses are not often encountered in clinical practice. We report a case of a 28-year-old woman who presented with a pelvic mass and obscure clinical signs. Imaging methods suggested that this tumor was most probably an ovarian mass of embryonic origin. After dissection by laparotomy, the microscopic examination showed typical futures of a neurilemoma (ancient schwannoma). The goal of the operating intervention is to excise the tumor avoiding major trauma, thus cooperation between surgeons is indispensable. The patient has had no motor or sensory disturbances after surgery.
Collapse
Affiliation(s)
- I Korkontzelos
- Department of Obstetrics & Gynecology, State General Hospital of Ioannina G. Chatzikosta, Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
12
|
Karabina E, Borredon ME. Synthesis of Hydroxyethers from Glycerol and Fatty Chains Epoxyalkanes in the Absence of Organic Solvent. SYNTHETIC COMMUN 1994. [DOI: 10.1080/00397919408011314] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|